Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $137.35. The company's market cap stands at 13.69B, with a P/E ratio of 32.48.
During the trading session on 2026-01-06, Neurocrine(NBIX) shares reached a daily high of $138.53 and a low of $135.95. At a current price of $137.35, the stock is +1.0% higher than the low and still -0.9% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.11M, versus its average volume of 854.07K.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
NBIX News
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...
RBC Capital analyst Brian Abrahams notes that Neurocrine’s (NBIX) CAH competitor Crinetics (CRNX) reported new phase II data from an additional cohort that were...
Neurocrine Biosciences (NBIX) is back in focus after the company reported that its pivotal Phase 3 KINECT DCP trial of valbenazine in dyskinetic cerebral palsy...
